3rd Annual Jefferson Urology Symposium: Men’s Health Forum

© The Canadian Journal of Urology TM : International Supplement, August 2020 anddefine clinical applicability but are not beingwidely adopted. One example of comparative prostate cancer biomarker testing is the recently completed Canary Prostate Active Surveillance Study (PASS). 26 This study examined the association of urinary biomarkers PCA3 and TMPRSS2:ERG (T2:ERG) with biopsy-based reclassification of men on active surveillance. Other factors to consider when deciding to use a specific biomarker are cost and insurance coverage. The field of precision medicine is rapidly evolving, and our symposium presentation focused on some of the more commonly used FDA approved markers. There are many other biomarkers under study in areas such as liquid biopsies for circulating DNA and the use of genetic testing for prostate cancer risk assessment and management of all stages of disease. 27,28 The future of these precision oncology initiatives will rely on the identification ofmore patient specific biomarkers. These new markers will exploit the unique inherited and somatic genomic characteristics of the patient and his prostate cancer to further guide diagnosis and treatment in all stages of disease. ** Editors note In May, 2020 two PARP inhibitors, rucaparib and olaparib, were approved formetastatic castrate resistant prostate cancerwith a deleterious BRCAor homologous recombination repair (HRR) gene mutation. References 1. Cancer Research UK. Prostate cancer incidence statistics. 2019. http://www.cancerresearchuk.org/health ‐professional/cancer‐ statistics/statistics‐by‐cancer‐type/prostate‐cancer/incidence. Accessed March 18, 2020. 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CACancer J Clin 2020;70(1):7-30. 3. Van Neste L, Hendriks RJ, Dijkstra S et al. Detection of high- grade prostate cancer using a urinary molecular biomarker- based risk score. Eur Urol 2016;70(5):740-748. 4. Cucchiara V, CooperbergMR, Dall’EraMet al. Genomicmarkers in prostate cancer decisionmaking. Eur Urol 2018;73(4):572-582. 5. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservativemanagement of clinically localized prostate cancer. JAMA 2005;293(17):2095-2101. 6. Draisma G, Boer R, Otto SJ et al. Lead times and over detection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-878. 7. Madalinska JB, Essink-BotML, de KoningHJ et al. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer . J Clin Oncol 2001;19(6):1619-1628. 8. Catalona WJ, PartinAW, Sanda MG et al. Amulticenter study of [-2]pro-prostate specific antigen combinedwith prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range [published correction appears in J Urol 2011;186(1):354]. J Urol 2011;185(5):1650-1655. 9. Mikolajczyk SD, Grauer LS, Millar LS et al. Aprecursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50(5):710-714. 10. Lin DW, Newcomb LF, Brown MD et al. Evaluating the four kallikrein panel of the 4Kscore for prediction of high-grade prostate cancer inmen in the Canary ProstateActive Surveillance Study. Eur Urol 2017;72(3):448-454. 11. Bussemakers MJ, van Bokhoven A, Verhaegh GW et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59(23):5975-5979. 12. Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. J Urol 2013;189(2):422-429. 13. De Luca S, Passera R, Cappia S et al. Fluctuation in prostate cancer gene 3 (PCA 3) score in men undergoing first or repeat biopsies. BJU Int 2014;114(6b):E56-E61. 14.Wei JT, Feng Z, Partin AW et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol 2014; 32(36):4066-4072. 15. Vickers AJ. Markers for the early detection of prostate cancer: some principles for statistical reporting and interpretation. J Clin Oncol 2014;32(36):4033-4034. 16. McKiernan J, DonovanMJ,Margolis Eet al.Aprospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients withprostate-specific antigen 2-10 ng/ml at initial biopsy. EurUrol 2018;74(6):731-738. 17.Wojno KJ, Costa FJ, Cornell RJ et al. Reduced rate of repeated prostate biopsies observed in ConfirmMDx clinical utility field study. Am Health Drug Benefits 2014;7(3):129-134. 18. Trock BJ, BrotzmanMJ, Mangold LAet al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 2012;110(1): 56-62. 19. Klein EA, Cooperberg MR, Magi-Galluzzi C et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014;66(3):550-560. 20. KimHL, Li P, Huang HC et al. Validation of the Deipher test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer ProstaticDis 2019;22(3):399-405. 21. Marascio J, Spratt DE, Zhang J et al. Prospective study to define the clinical utility andbenefit of Decipher testing inmen following prostatectomy. Prostate Cancer Prostatic Dis 2020;23(2):295-302. 22. Erho N, CrisanA, Vergara IAet al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS ONE 2013:8(6):e66855. 23. Health Quality Ontario. Prolaris cell cycle progression test for localized prostate cancer: a health technology assessment. Ont Health Technol Assess Ser 2017;17(6):1-75. 24. SarwasM, Semenas J, Miftakhova R et al. Targeted suppression of AR-V7usingPIP5K1ainhibitorovercomesenzalutamideresistance in prostate cancer cells. Oncotarget 2016;7(39):63065-63081. 25. Scher HI, Lu D, Schreiber NA et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2016;2(11):1441-1449. 26. Newcomb LF, Zheng Y, Faino AV et al Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis 2019;22(3):438-445 27. Moreno JG, Gomella LG. Evolution of the liquid biopsy in metastatic prostate cancer. Urology 2019;132:1-9. 28. Giri VN, Hyatt C, Gomella LG. Germline testing for men with prostate cancer: navigating an expanding newworld of genetic evaluation for precision therapy and precision management. J Clin Oncol 2019;37(17):1455-1459. 27 An overview of biomarkers in the diagnosis and management of prostate cancer